deltatrials
Completed PHASE3 NCT00119652

Seroquel in Bipolar Depression Versus SSRI

Multicentre, Double-blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)

Sponsor: AstraZeneca

Conditions Bipolar Depression Bipolar Disorder Depression
Interventions mood stabilizing activity paroxetine quetiapine fumarate (Seroquel)
Updated 7 times since 2017 Last updated: Jan 3, 2013 Started: May 31, 2005 Completion: May 31, 2007

This PHASE3 trial investigates Bipolar Depression and Bipolar Disorder and is currently completed. AstraZeneca leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Change History

7 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

May 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece, Atlanta, United States, Austin, United States, Bellevue, United States, Benoni, South Africa, Bogotá, Colombia, Brisbane, Australia, Bucharest, Romania, Cape Town, South Africa, Cincinnati, United States and 45 more location s